相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
Vedang Murthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial
Anthony D'Amico et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer
Spyridon P. Basourakos et al.
FRONTIERS IN ONCOLOGY (2021)
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High -risk Prostate Carcinoma: A Phase III Randomized Study
Daniel W. Lin et al.
EUROPEAN UROLOGY (2020)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer
James A. Eastham et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
Seth A. Rosenthal et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial
Pirkko-Liisa Kellokumpu-Lehtinen et al.
EUROPEAN UROLOGY (2019)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
791OUpdated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up
K Fizazi et al.
ANNALS OF ONCOLOGY (2018)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy A Secondary Analysis of a Randomized Clinical Trial
Trevor J. Royce et al.
JAMA ONCOLOGY (2017)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer
Mark K. Buyyounouski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Christopher U. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Michel Bolla et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Androgen suppression and radiation vs radiation alone for prostate cancer - A randomized trial
Anthony V. D'Amico et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial
James W. Denham et al.
LANCET ONCOLOGY (2008)
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial
AV D'Amico et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
